PL3262037T3 - Nowa pochodna chinoliny do zastosowania w leczeniu i w zapobieganiu zakażeniom wirusowym - Google Patents

Nowa pochodna chinoliny do zastosowania w leczeniu i w zapobieganiu zakażeniom wirusowym

Info

Publication number
PL3262037T3
PL3262037T3 PL16705515T PL16705515T PL3262037T3 PL 3262037 T3 PL3262037 T3 PL 3262037T3 PL 16705515 T PL16705515 T PL 16705515T PL 16705515 T PL16705515 T PL 16705515T PL 3262037 T3 PL3262037 T3 PL 3262037T3
Authority
PL
Poland
Prior art keywords
prevention
treatment
viral infections
quinoline derivative
new quinoline
Prior art date
Application number
PL16705515T
Other languages
English (en)
Inventor
Didier Scherrer
Aude Garcel
Noëlie CAMPOS
Jamal Tazi
Audrey Vautrin
Florence Mahuteau
Romain Najman
Pauline Fornarelli
Original Assignee
Abivax
Cnrs Centre National De La Recherche Scientifique
Institut Curie
Université De Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax, Cnrs Centre National De La Recherche Scientifique, Institut Curie, Université De Montpellier filed Critical Abivax
Publication of PL3262037T3 publication Critical patent/PL3262037T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
PL16705515T 2015-02-23 2016-02-19 Nowa pochodna chinoliny do zastosowania w leczeniu i w zapobieganiu zakażeniom wirusowym PL3262037T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305274.1A EP3059236A1 (en) 2015-02-23 2015-02-23 A new quinoline derivative for use in the treatment and prevention of viral infections
EP16705515.1A EP3262037B1 (en) 2015-02-23 2016-02-19 A new quinoline derivative for use in the treatment and prevention of viral infections
PCT/EP2016/053532 WO2016135052A1 (en) 2015-02-23 2016-02-19 A new quinoline derivative for use in the treatment and prevention of viral infections

Publications (1)

Publication Number Publication Date
PL3262037T3 true PL3262037T3 (pl) 2020-10-19

Family

ID=52629497

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16705515T PL3262037T3 (pl) 2015-02-23 2016-02-19 Nowa pochodna chinoliny do zastosowania w leczeniu i w zapobieganiu zakażeniom wirusowym

Country Status (22)

Country Link
US (1) US10329317B2 (pl)
EP (2) EP3059236A1 (pl)
JP (1) JP6797126B2 (pl)
KR (1) KR102583506B1 (pl)
CN (1) CN107531681B (pl)
AU (1) AU2016223687B2 (pl)
BR (1) BR112017017500B1 (pl)
CA (1) CA2975577C (pl)
CU (1) CU24525B1 (pl)
DK (1) DK3262037T3 (pl)
ES (1) ES2785374T3 (pl)
HR (1) HRP20200649T1 (pl)
HU (1) HUE048577T2 (pl)
LT (1) LT3262037T (pl)
MX (1) MX381187B (pl)
PL (1) PL3262037T3 (pl)
PT (1) PT3262037T (pl)
RS (1) RS60369B1 (pl)
RU (1) RU2723013C2 (pl)
SI (1) SI3262037T1 (pl)
WO (1) WO2016135052A1 (pl)
ZA (1) ZA201705633B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
US20190034990A1 (en) * 2017-07-26 2019-01-31 International Business Machines Corporation Information insight system for providers of products or services
EP3669874A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
EP3669873A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
EP3881844A1 (en) * 2020-03-20 2021-09-22 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
BR112022018793A2 (pt) * 2020-03-20 2022-11-29 Abivax Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae
EP3884946A1 (en) * 2020-03-25 2021-09-29 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
WO2022247920A1 (zh) 2021-05-27 2022-12-01 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
EP4201948A1 (en) 2021-12-21 2023-06-28 Abivax Method of preparation of 1-(n-(quinolin-2-yl)-(phenylamino)-1-deoxy-beta-d-glucopyranuronic acid derivatives
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
EP4215196A1 (en) * 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
TW202436295A (zh) * 2022-11-25 2024-09-16 大陸商江蘇恒瑞醫藥股份有限公司 喹啉胺類化合物的可藥用鹽、晶型及其製備方法
TW202436296A (zh) * 2022-11-25 2024-09-16 大陸商江蘇恒瑞醫藥股份有限公司 喹啉胺類化合物晶型及其製備方法
CN116617226B (zh) * 2023-06-21 2024-06-25 湖北工业大学 新型吲哚喹啉衍生物作为肠道病毒71型抑制剂的应用
EP4785940A1 (en) 2025-01-31 2026-08-05 Abivax Combination of obefazimod and its derivatives with a tnf alpha-inhibitor
EP4785941A1 (en) 2025-01-31 2026-08-05 Abivax Combination of obefazimod and its derivatives with a alpha4beta7 anti-integrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
CN102625804B (zh) * 2009-06-12 2015-04-08 Abivax公司 用于治疗aids的化合物
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
CA2916623C (en) * 2013-07-05 2021-09-14 Abivax Bicyclic compounds useful for treating diseases caused by retroviruses
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS

Also Published As

Publication number Publication date
KR20170129698A (ko) 2017-11-27
KR102583506B1 (ko) 2023-09-26
US10329317B2 (en) 2019-06-25
RU2017128643A (ru) 2019-03-25
WO2016135052A1 (en) 2016-09-01
RS60369B1 (sr) 2020-07-31
RU2723013C2 (ru) 2020-06-08
SI3262037T1 (sl) 2020-09-30
ZA201705633B (en) 2018-12-19
US20180030078A1 (en) 2018-02-01
CN107531681B (zh) 2020-11-24
JP2018507215A (ja) 2018-03-15
BR112017017500B1 (pt) 2023-04-04
AU2016223687A1 (en) 2017-08-31
CA2975577A1 (en) 2016-09-01
ES2785374T3 (es) 2020-10-06
LT3262037T (lt) 2020-07-10
MX2017010506A (es) 2017-11-13
EP3262037B1 (en) 2020-02-12
BR112017017500A2 (pt) 2018-04-17
DK3262037T3 (da) 2020-05-04
MX381187B (es) 2025-03-12
JP6797126B2 (ja) 2020-12-09
HUE048577T2 (hu) 2020-07-28
CA2975577C (en) 2020-04-07
PT3262037T (pt) 2020-04-09
RU2017128643A3 (pl) 2019-04-15
CU24525B1 (es) 2021-06-08
CN107531681A (zh) 2018-01-02
EP3059236A1 (en) 2016-08-24
AU2016223687B2 (en) 2020-03-19
EP3262037A1 (en) 2018-01-03
CU20170109A7 (es) 2018-02-08
HRP20200649T1 (hr) 2020-10-16

Similar Documents

Publication Publication Date Title
ZA201705633B (en) A new quinoline derivative for use in the treatment and prevention of viral infections
IL272820B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
IL259570A (en) Combined therapy and their uses and methods
IL273932A (en) Methods of treatment and prevention of viral infection
IL247252B (en) History of isoquinoline and its use
ZA201705634B (en) Quinoline derivatives for use in the treatment or prevention of viral infection
IL263368A (en) Prevention and treatment of viral infections
IL249660A0 (en) Methods for treating hepatitis b virus and hepatitis d virus infections
GB2538923B (en) A therapeutic agent for use in the treatment of infections
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
IL247938A0 (en) Onconas for use in the treatment or prevention of viral infections
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL242317B (en) History of Pyridone for the treatment of viral infections and other diseases
GB201418809D0 (en) Therapeutic agents and uses thereof
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
HUE045242T2 (hu) Vírusfertõzések megelõzésére és terápiájára szánt ágens
EP3102205A4 (en) Treating flavivirus infections with amodiaquine and derivatives thereof
AU2014900488A0 (en) Agents and methods for inhibiting virus infection
AU2015900546A0 (en) Agents and methods for inhibiting virus infection